Basilea Pharmaceutica Ltd. Logo

Anti-Infectives 2002

  • Azoulay-Dupuis E, Mohler J, Bédos J, Schmitt-Hoffmann A, Shapiro S. Efficacy of BAL5788, a Prodrug of Cephalosporin BAL9141, in a Mouse Model of Acute Pneumococcal Pneumonia. 42nd ICAAC 2002. Poster F-335.
  • Bernabeu A, Shapiro S, Villalain J. A MAS-NMR study of the location of (+)-totarol, a diterpenoid bioactive molecule, in phospholipid model membranes. Chemistry and Physics of Lipids 2002; 119(1-2): 33–39.
  • Dreier J, Breitmaier EB, Gocke E, Apfel CM, Page MGP. Direct influence of S9 liver homogenate on fluorescence signals: impact on practical applications in a bacterial genotoxicity assay. Mutation Research 2002; 513(1-2): 169–182.
  • Entenza JM, Hohl P, Heinze-Krauss I, Glauser MP, Moreillon P. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Ag Chemother 2002; 46: 171–177.
  • Guo GJ, Nahong Q, Page MGP. Universal restriction site-free cloning method using chimeric primers. BioTechniques 2002; 32(3): 516–520.
  • Hujer AM, Page MGP, Helfand MS, Yeiser B, Bonomo RA. Development of a sensitive and specific enzyme-linked immunosorbent assay for detecting and quantifying CMY-2 and SHV beta-lactamases. Journal of Clinical Microbiology 2002; 40(6): 1947–1957.
  • Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J of Antimicrob Chemother, 2002; 50: 915–932.
  • Mouton JW, Schmitt-Hoffmann A, Shapiro S, Nashed N, Punt NC. Monte Carlo Predictions of dosage regimens for BAL5788, a new broad-spectrum cephalosporin active against MRSA. 42nd ICAAC 2002. Poster F-336.
  • Ohwada J, Tsukazaki M, Hayase T, et al. RO009855 a Novel Water Soluble Azole Prodrug for Parenteral and Oral Administration (I) Design, Synthesis, Physicochemical Properties and Bioconversion. 42nd ICAAC 2002. Poster: F-820.
  • Schmitt-Hoffmann A, Kovacs P, Roos B, et al. Preliminary Pharmacokinetics and Safety of BAL9141 after Single Ascending Dose Infusions of BAL5788 in Volunteers. 42nd ICAAC 2002. Poster F-337.
  • Shapiro S, Giertsen E, Guggenheim B. An in vitro Oral Biofilm Model for Comparing the Efficacy of Antimicrobial Mouthrinses. Caries Research 2002; 36(2): 93–100.
  • Wagner C, De Saizieu A, Schonfeld H-J, Kamber M, Lange R, Thompson CJ, Page MG. Genetic analysis and functional characterization of the Streptococcus pneumoniae vic operon. Infection and Immunity 2002; 70(11): 6121–6128.
  • Wootton M, Bowker KE, Holt HA, MacGowan AP. BAL9141, a new broad spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with ten other antimicrobials. J Antimicrob Chemother 2002; 49: 535–539.
  • Yamazaki T, Tsukaguchi T, Ono Y, et al. RO0098557, a Novel Water Soluble Azole Prodrug for Parenteral and Oral Administration (II) Prodrug Principle and Broad Spectrum Antifungal. 42nd ICAAC 2002. Poster F-821.
  • Zbinden R, Punter V, von Graevenitz A. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against Gram-negative nonfermenters. Antimicrob Ag Chemother 2002; 46: 871–874.